SLV-306 Solvay

Current Opinion in Investigational Drugs

Volumn 4, Issue 3, 2003, Pages 329-332

  Tabrizchi, Reza ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

2 [3 [1 (2 CARBOXY 4 PHENYLBUTYL)CYCLOPENTANECARBOXAMIDO] 2,3,4,5 TETRAHYDRO 2 OXO 1H 1 BENZAZEPIN 1 YL]ACETIC ACID; BENZAZEPINE N ACETIC ACID DERIVATIVE; BENZOTHIAZEPINE N ACETIC ACID DERIVATIVE; BENZOXAZEPINE N ACETIC ACID DERIVATIVE; DAGLUTRIL; ENDOTHELIN CONVERTING ENZYME INHIBITOR; ENKEPHALINASE INHIBITOR; KC 12792; PLACEBO; UNCLASSIFIED DRUG;

BELGIUM; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE MODEL; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MARKETING; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; ESSENTIAL HYPERTENSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INHIBITION KINETICS; NONHUMAN; PATENT; REVIEW; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ASPARTIC ENDOPEPTIDASES; BENZAZEPINES; CLINICAL TRIALS; HUMANS; HYPERTENSION; METALLOENDOPEPTIDASES; NEPRILYSIN;

EID: 0038755141     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. cp) rats. Tofovic SP, Li P, Jackson EK Pharmacologist 1997 39 1 76 Describes the hemodynamics, renal function and neurohumoral activity of SLV-306.
2. 258678 Cardiovascular and hormonal effects of chronic neutral endopeptidase inhibition in dogs with heart failure. Udvary E, Rozsa Z, Lang J, Thormaechlen D, Papp JG J Mol Cell Cardiol 1997 29 5 Abs 56
3. 330116 Annual Report 1998 - Solvay. Solvay SA Annual Report 1998 December 31
4. 422350 Solvay's novel therapeutic agent SLV306 shows its early promise for the treatment of hypertension and congestive heart failure. Solvay Pharmaceuticals Inc Press Release 2001 September 14
5. 438027 Solvay Pharmaceuticals - A fundamental strategic change for Solvay. Solvay SA Company Presentation 2001 September 14
6. 454526 First demonstration in humans of systemic neutral endopeptidase and endothelin converting enzyme inhibition using a new, orally active, dual metalloprotease inhibitor, SLV 306. Seed A, Kuc R, Davenport A, Hillier C, Essers H, McMurray J Heart 2002 87 Suppl 2 P68 Describes phase I clinical data for SLV-306 in healthy male volunteers.
7. 464521 British Pharmacological Society - Autumn Meeting, Glasgow, UK. Lawson K IDDB Meeting Report 2002 September 3-6
8. 472715 Nonpeptidic endothelin-converting enzyme inhibitors and their potential therapeutic applications. Jeng AY, Mulder P, Kwan AL, Battistini B Can J Physiol Pharmacol 2002 80 5 440-449
9. 472731 Pharmacology of the active metabolite of SLV 306 - A mixed inhibitor of NEP and ECE. Meil J, Wurl M, Thormaehlen D, Rose H Arch Pharmacol 1998 358 1 Suppl 2 R513
10. 472732 In vivo results with SLV 306 an orally active inhibitor of NEP and ECE. Meil J, Rupp H, Thormaehlen D, Rose H Arch Pharmacol 1998 358 1 Suppl 2 R514
11. 473228 Evidence that a novel orally active NEP/ECE inhibitor blocks the vasoconstrictor response to big endothelin in human resistance arteries. Seed A, Hillier C, Berry C, Johnston F, Petrie M, McMurray JJV J Am Coll Cardiol 2001 37 2 237A-238A
12. 477350 The physiological and pathophysiological modulation of the endocrine function of the heart. De Bold AJ, Ma KK, Zhang Y, De Bold ML, Bensimon M, Khoshbaten A Can J Physiol Pharmacol 2001 79 8 705-714
13. 477351 Natriuretic peptides. Levin ER, Gardner DG, Samson WK N Engl J Med 1998 339 5 321-327
14. 477352 Natriuretic peptide signalling: Molecular and cellular pathways to growth regulation. Silberbach M, Roberts CT Jr Cell Signal 2001 13 4 221-231
15. 477353 Role of endopeptidase-24.11 in activation of atrial natriuretic peptide. Kenny AJ, Stephenson SL FEBS Lett 1988 232 1 1-8
16. 477354 Inactivation of atrial natriuretic factor by the renal brush border. Olins GM, Spear KL, Siegel NR, Zurcher-Neely HA Biochim Biophys Acta 1987 907 1 97-100
17. 477355 Comparison between the vasoactive actions of endothelin and arginine vasopressin in pithed rats after pretreatment with BAY K 8644, nifedipine or pertussis toxin. Tabrizchi R, Triggle CR J Pharmacol Exp Ther 1990 253 1 272-276
18. 477357 In vivo hemodynamic and inotropic effects of the endothelin B agonist IRL 1620. Beyer ME, Slesak G, Hoffmeister HM J Cardiovasc Pharmacol 1995 25 26 Suppl 3 S190-S192
19. 477358 ET-1 infusion increases systemic vascular resistance and depresses cardiac output in patients with chronic hypoxaemia and pulmonary hypertension. Franco-Cereceda A, Holm P, Brodin LA, Liska J, Larsen FF Scand Cardiovasc J Suppl 1999 33 3 151-156
20. 477359 Proinflammatory effects of angiotensin II and endothelin: Targets for progression of cardiovascular and renal diseases. Luft FC Curr Opin Nephrol Hypertens 2002 11 1 59-66
21. 478580 Questcor adopts shareholder rights plan. Press Release 2003 February 12
22. 481843 European Pharma hybrids - Product profiles. Blair P et al Schroder Salomon Smith Barney UK/Europe 2003 January 28